EpiCept’s Nasdaq listing endangered
-
- April
- 8
EpiCept Corp. of Eastview said yesterday that its listing on the Nasdaq market is endangered. The drug researcher said it is out of compliance with Nasdaq rules that require a market cap of $35 million for 10 consecutive trading days. EpiCept said it is working to regain compliance by a May 5 deadline.
This entry was posted
on Tuesday, April 8th, 2008 at 5:20 pm by Jerry Gleeson.
You can follow any responses to this entry through the RSS 2.0 feed.
Print
|
Email
Leave a Reply
It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the
Terms of Service.